| ASSET | YEAR | % RETURN |
|---|---|---|
Altimmune (ALT) | 2017 | 1,570,952.63% |
HIVE Digital Technologies (HIVE) | 2017 | 3,814.29% |
TSS, Inc Common Stock (TSSI) | 2017 | 1,200% |
Lexinfintech (LX) | 2017 | 1,077.89% |
Gravity (GRVY) | 2017 | 801.72% |
XOMA Royalty (XOMA) | 2017 | 747.62% |
Cronos (CRON) | 2017 | 592.83% |
Palvella Therapeutics (PVLA) | 2017 | 447.1% |
Esperion Therapeutics (ESPR) | 2017 | 414.38% |
Xunlei Ltd Adr (XNET) | 2017 | 298.7% |
Global Industrial (GIC) | 2017 | 281.26% |
Assembly Biosciences (ASMB) | 2017 | 276.93% |
BioLife Solutions (BLFS) | 2017 | 270.37% |
Pulse Biosciences (PLSE) | 2017 | 263.08% |
Avalo Therapeutics (AVTX) | 2017 | 259.55% |
Uniqure (QURE) | 2017 | 247.34% |
Canopy Growth (CGC) | 2017 | 243.74% |
Lendingtree (TREE) | 2017 | 230.86% |
Ridgepost Capital (RPC) | 2017 | 226.04% |
Astrana Health (ASTH) | 2017 | 220% |
Puma Biotechnology (PBYI) | 2017 | 216.32% |
Abeona Therapeutics (ABEO) | 2017 | 210.78% |
Daqo New Energy Corp ADR (DQ) | 2017 | 202.03% |
Lithium Argentina (LAR) | 2017 | 196.39% |
UroGen Pharma (URGN) | 2017 | 180.2% |
Small-cap stocks are treated as having a market cap between $300M and $2B.